Q4 2026 Financial Highlights (3 Months Ended
- Revenue was
$8.8 million , a quarterly record, compared to$6.2 million in the same quarter of the previous fiscal year, representing growth of approximately 42%, and compared to$8.7 million in the most recent sequential quarter. - Production revenue was
$8.0 million , a quarterly record, compared to$5.1 million in the same quarter of the previous fiscal year, representing growth of approximately 57%, and compared to$7.6 million in the most recent sequential quarter. - Gross margin was 25.3% compared to 13.0% in the same quarter of the previous fiscal year and compared to 23.6% in the most recent sequential quarter.
- Net loss for the quarter was
$(0.1) million , compared to a net loss of$(1.4) million in the same quarter of the previous fiscal year and a net loss of$(0.1) million in the most recent sequential quarter. - Adjusted EBITDA was
$0.4 million for the quarter compared to$(0.9) million in the same quarter of the previous fiscal year and$0.3 million in the most recent sequential quarter.
FY 2026 Financial Highlights (Year Ended
- Revenue was
$31.5 million , a fiscal year record, compared to$19.1 million in the previous fiscal year, representing growth of approximately 65%. - Production revenue doubled to
$28.1 million compared to$14.2 million in the previous fiscal year. - Gross margin was 17.2% compared to 17.8% in the previous fiscal year.
- Net loss for the fiscal year declined to
$(3.6) million , or$(0.43) per share, from$(5.8) million , or$(0.85) per share, in the previous fiscal year. - Adjusted EBITDA was
$(2.1) million for the fiscal year compared to$(3.7) million in the previous fiscal year, an improvement of approximately$1.6 million . - Cash and cash equivalents were
$9.8 million atJune 30, 2026 , compared to$1.8 million atJune 30, 2025 .
Recent Additional Highlights
- Achieved record quarterly revenue from the Company’s existing top-tier aerospace customer and continued strong production of its single-use cystoscopy surgery system.
- Continued ramping production under the previously announced
$3.5 million follow-on order for the single-use ophthalmic program. - Received a
$1.3 million follow-on production order from a large defense company. - Recently announced an initial engineering order from a
U.S . space technology company. - Continued strengthening the Company’s leadership team with the appointment of
Peter Thier as Senior Vice President of Sales and Marketing.
FY 2027 Financial Guidance (Year Ending
- The Company expects fiscal year 2027 revenue to be in the range of
$30 million to$33 million , similar to fiscal year 2026. The outlook reflects a pause in demand from the Company’s existing satellite customer with growth in single-use medical device programs, renewed defense production, additional programs transitioning into production and new engineering engagements expecting to partly offset this reduction. The Company expects a stronger second half of the year as orders are expected to resume from the existing satellite customer. - The Company expects fiscal year 2027 Adjusted EBITDA to be in a range of
$(1.2) million to$(1.7) million .
“Fiscal 2026 was a year of transformation for
“Rebuilding our product development pipeline is a priority led by our new SVP of Sales and Marketing. We received an initial engineering order from a second satellite customer. Although it is still early, we see the potential to build another meaningful, long-term production relationship.”
The following table summarizes the fourth quarter and fiscal year results for the periods ended
| Three Months Ended 2026 | Three Months Ended 2025 | Year Ended 2026 | Year Ended 2025 | |
| Revenues | $8,774,474 | $6,181,342 | $31,531,765 | $19,091,269 |
| Cost of goods sold | 6,550,806 | 5,382,155 | 26,100,545 | 15,686,836 |
| Gross profit | 2,223,668 | 799,187 | 5,431,220 | 3,404,433 |
| Total operating expenses | 2,330,228 | 2,155,229 | 8,939,828 | 8,955,724 |
| Operating income (loss) | (106,560) | (1,356,042) | (3,508,608) | (5,551,291) |
| Interest income (expense), net | (971) | (44,577) | (116,325) | (227,019) |
| Income (loss) before income taxes | (107,531) | (1,400,619) | (3,624,933) | (5,778,310) |
| Income tax expense (benefit) | (3,744) | 1,936 | 4,958 | 1,936 |
| Net Loss | $(103,787) | $(1,402,555) | $(3,629,891) | $(5,780,246) |
| Earnings (loss) per share, basic | ||||
| Earnings (loss) per share, diluted | ||||
| Weighted average shares, basic | 10,943,843 | 7,690,084 | 8,530,599 | 6,790,466 |
| Weighted average shares, diluted | 10,943,843 | 7,690,084 | 8,530,599 | 6,790,466 |
Conference Call Details
Date and Time:
Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or (412) 317-5705.
Live Webcast Information: Interested parties can access the conference call via a live webcast, which will be available at https://app.webinar.net/0E4e7l07PjV.
Replay: A teleconference replay of the call will be available for seven days at (855) 669-9658 or (412) 317-0088, replay access code 7128172. A webcast replay will be available at https://app.webinar.net/0E4e7l07PjV.
About
Founded in 1982,
Non-GAAP Financial Measures
This non-GAAP financial measure assists
Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information calculated in accordance with GAAP. Investors are encouraged to review the reconciliation of non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measure presented above to GAAP results has been provided in the financial tables included with this press release.
About Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
Balance Sheets at | ||||||||
| 2026 | 2025 | |||||||
| ASSETS | ||||||||
| Current Assets: | ||||||||
| Cash and cash equivalents | $ | 9,841,142 | $ | 1,773,735 | ||||
| Accounts receivable, net of allowance for credit losses of | 5,944,412 | 4,336,730 | ||||||
| Inventories, net | 3,829,414 | 3,562,112 | ||||||
| Prepaid expenses | 494,488 | 385,390 | ||||||
| Total current assets | 20,109,456 | 10,057,967 | ||||||
| Fixed Assets: | ||||||||
| Machinery and equipment | 3,410,813 | 3,385,958 | ||||||
| Leasehold improvements | 1,226,171 | 871,356 | ||||||
| Furniture and fixtures | 645,046 | 538,428 | ||||||
| 5,282,030 | 4,795,742 | |||||||
| Less—Accumulated depreciation and amortization | 4,394,317 | 4,261,950 | ||||||
| Net fixed assets | 887,713 | 533,792 | ||||||
| Operating lease right-of-use asset | 2,300,866 | 141,825 | ||||||
| Patents, net | 212,889 | 232,493 | ||||||
| 8,824,210 | 8,824,210 | |||||||
| Total other assets | 11,337,965 | 9,198,528 | ||||||
| TOTAL ASSETS | $ | 32,335,134 | $ | 19,790,287 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Current portion of capital lease obligation | $ | – | $ | 27,368 | ||||
| Current maturities of long-term debt | 577,898 | 577,898 | ||||||
| Accounts payable | 3,582,674 | 2,909,100 | ||||||
| Customer advances | 2,498,501 | 1,821,929 | ||||||
| Accrued compensation and other | 1,843,368 | 764,004 | ||||||
| Operating lease liability | 325,500 | 50,995 | ||||||
| Total current liabilities | 8,827,941 | 6,151,294 | ||||||
| Long-term debt, net of current maturities | 711,305 | 1,289,205 | ||||||
| Operating lease liability, net of current portion | 2,446,576 | 90,954 | ||||||
| Total liabilities | 11,985,822 | 7,531,453 | ||||||
| Stockholders’ Equity: | ||||||||
| Common stock, | 109,728 | 77,147 | ||||||
| Additional paid-in capital | 80,840,105 | 69,152,317 | ||||||
| Accumulated deficit | (60,600,521 | ) | (56,970,630 | ) | ||||
| Total stockholders’ equity | 20,349,312 | 12,258,834 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 32,335,134 | $ | 19,790,287 | ||||
Statements of Operations for the Years Ended | ||||||||
| 2026 | 2025 | |||||||
| Revenues | $ | 31,531,765 | $ | 19,091,269 | ||||
| Cost of goods sold | 26,100,545 | 15,686,836 | ||||||
| Gross profit | 5,431,220 | 3,404,433 | ||||||
| Research and development expenses, net | 1,033,156 | 1,157,963 | ||||||
| Selling, general and administrative expenses | 7,906,672 | 7,797,761 | ||||||
| Total operating expenses | 8,939,828 | 8,955,724 | ||||||
| Operating loss | (3,508,608 | ) | (5,551,291 | ) | ||||
| Other expense | ||||||||
| Interest expense | (148,129 | ) | (227,019 | ) | ||||
| Interest income | 31,804 | - | ||||||
| Loss before provision for income taxes | (3,624,933 | ) | (5,778,310 | ) | ||||
| Provision for income taxes | 4,958 | 1,936 | ||||||
| Net loss | $ | (3,629,891 | ) | $ | (5,780,246 | ) | ||
| Loss per share: | ||||||||
| Basic and fully diluted | $ | (0.43 | ) | $ | (0.85 | ) | ||
| Weighted average common shares outstanding: | ||||||||
| Basic and fully diluted | 8,530,599 | 6,790,466 | ||||||
Statements of Stockholders’ Equity for the Years Ended | ||||||||||||||||||||
| Number of Shares | Common Stock | Additional Paid-in Capital | Accumulated Deficit | Total Stockholders’ Equity | ||||||||||||||||
| Balance, | 6,073,939 | $ | 60,739 | $ | 61,197,433 | $ | (51,190,384 | ) | $ | 10,067,788 | ||||||||||
| Issuance of common stock in a registered direct offering | 1,538,368 | 15,384 | 6,254,752 | – | 6,270,136 | |||||||||||||||
| Proceeds from exercise of stock option | 71,979 | 721 | 88,329 | – | 89,050 | |||||||||||||||
| Issuance of common stock for consulting services and employees | 30,415 | 303 | 151,395 | – | 151,698 | |||||||||||||||
| Stock-based compensation | – | – | 1,460,408 | – | 1,460,408 | |||||||||||||||
| Net loss | – | – | – | (5,780,246 | ) | (5,780,246 | ) | |||||||||||||
| Balance, | 7,714,701 | $ | 77,147 | $ | 69,152,317 | $ | (56,970,630 | ) | $ | 12,258,834 | ||||||||||
| Issuance of common stock in public offering | 3,194,444 | 31,944 | 10,598,734 | – | 10,630,678 | |||||||||||||||
| Proceeds from exercise of stock option | 40,294 | 404 | 39,595 | – | 39,999 | |||||||||||||||
| Issuance of common stock for employee services | 23,353 | 233 | 100,267 | – | 100,500 | |||||||||||||||
| Stock-based compensation | – | – | 949,192 | – | 949,192 | |||||||||||||||
| Net loss | – | – | – | (3,629,891 | ) | (3,629,891 | ) | |||||||||||||
| Balance, | 10,972,792 | $ | 109,728 | $ | 80,840,105 | $ | (60,600,521 | ) | $ | 20,349,312 | ||||||||||
Statements of Cash Flows For the Years Ended | ||||||||
| 2026 | 2025 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (3,629,891 | ) | $ | (5,780,246 | ) | ||
| Adjustments to reconcile net loss to net cash (used in) provided by operating activities- | ||||||||
| Depreciation and amortization | 279,277 | 212,439 | ||||||
| Stock-based compensation expense | 1,139,692 | 1,612,106 | ||||||
| Non-cash legal expense | – | 34,881 | ||||||
| Non-cash interest expense | 18,433 | 11,563 | ||||||
| Non-cash operating lease expense | 252,336 | 124 | ||||||
| Loss on disposal of fixed assets | 34,506 | – | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable, net | (1,607,682 | ) | (791,239 | ) | ||||
| Inventories | (267,302 | ) | (694,012 | ) | ||||
| Prepaid expenses | (109,098 | ) | (86,026 | ) | ||||
| Accounts payable | 673,574 | 1,511,787 | ||||||
| Contract liabilities | 676,572 | 649,579 | ||||||
| Accrued compensation and other | 989,364 | (76,658 | ) | |||||
| Net cash used in operating activities | (1,550,219 | ) | (3,395,702 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Additional patent costs | (5,564 | ) | (6,264 | ) | ||||
| Proceeds from sale of fixed assets | 3,000 | – | ||||||
| Purchases of property and equipment | (426,786 | ) | (227,209 | ) | ||||
| Net cash used in investing activities | (429,350 | ) | (233,473 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Payment of capital lease obligations | (27,368 | ) | (41,114 | ) | ||||
| Principal payments of long-term debt | (596,333 | ) | (280,440 | ) | ||||
| Payment of debt issuance costs | – | (40,000 | ) | |||||
| Repayments on line of credit | – | (1,000,000 | ) | |||||
| Gross proceeds from registered direct offerings of common stock | – | 6,270,136 | ||||||
| Proceeds from public offering of common stock, net | 10,630,678 | – | ||||||
| Gross proceeds from exercise of stock options | 39,999 | 89,050 | ||||||
| Net cash provided by financing activities | 10,046,976 | 4,997,632 | ||||||
| Net increase in cash and cash equivalents | 8,067,407 | 1,368,457 | ||||||
| Cash and cash equivalents, beginning of year | 1,773,735 | 405,278 | ||||||
| Cash and cash equivalents, end of year | $ | 9,841,142 | $ | 1,773,735 | ||||
| Supplemental disclosure of cash flow information: | ||||||||
| Cash paid during the year for income taxes | $ | 2,600 | $ | 1,936 | ||||
| Cash paid during the year for interest | $ | 129,696 | $ | 216,456 | ||||
| Leasehold improvements financed by landlord | $ | 218,750 | $ | – | ||||
| Issuance of common stock for consulting and employee services | $ | 100,500 | $ | 151,698 | ||||
| Stock based compensation for employee services included in accrued compensation and other | $ | 90,000 | $ | – | ||||
| Operating right-of-use assets obtained in exchange for operating lease liabilities | $ | 2,632,584 | $ | 133,650 | ||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | ||||||||||||||||
| ADJUSTED EBITDA | ||||||||||||||||
| Three Months Ended | Year Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Net Loss (GAAP) | $ | (103,787 | ) | $ | (1,402,555 | ) | $ | (3,629,891 | ) | $ | (5,780,246 | ) | ||||
| Stock based compensation | 397,193 | 439,873 | 1,139,692 | 1,612,106 | ||||||||||||
| Depreciation and amortization | 64,329 | 59,226 | 279,277 | 212,439 | ||||||||||||
| Income Taxes | (3,744 | ) | 1,936 | 4,958 | 1,936 | |||||||||||
| Interest Expense | 32,775 | 44,577 | 148,129 | 227,019 | ||||||||||||
| Interest Income | (31,804 | ) | - | (31,804 | ) | - | ||||||||||
| Adjusted EBITDA (non-GAAP) | $ | 354,962 | $ | (856,943 | ) | $ | (2,089,639 | ) | $ | (3,726,746 | ) | |||||
Source: 